Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) FCF Margin: 2012-2025

Historic FCF Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -52.54%.

  • Enanta Pharmaceuticals' FCF Margin rose 7994.00% to -52.54% in Q3 2025 from the same period last year, while for Sep 2025 it was -49.24%, marking a year-over-year increase of 9375.00%. This contributed to the annual value of -49.24% for FY2025, which is 9375.00% up from last year.
  • Enanta Pharmaceuticals' FCF Margin amounted to -52.54% in Q3 2025, which was down 155.46% from 94.74% recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year FCF Margin high stood at 94.74% for Q2 2025, and its period low was -181.45% during Q2 2023.
  • In the last 3 years, Enanta Pharmaceuticals' FCF Margin had a median value of -121.33% in 2023 and averaged -107.39%.
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by 11,793bps in 2022, then soared by 21,149bps in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' FCF Margin (Quarterly) stood at -49.31% in 2021, then tumbled by 11,519bps to -164.50% in 2022, then skyrocketed by 2,133bps to -143.17% in 2023, then tumbled by 746bps to -150.63% in 2024, then skyrocketed by 7,994bps to -52.54% in 2025.
  • Its FCF Margin was -52.54% in Q3 2025, compared to 94.74% in Q2 2025 and -107.37% in Q1 2025.